The Chargers activated Apple (hamstring) from IR on Friday. Apple remains officially listed as questionable for Saturday's road AFC wild-card matchup against the Texans, but his activation from IR ...

The Los Angeles Chargers today activated cornerback Eli Apple and wide receiver Simi Fehoko from Reserve/Injured; Designated for Return. In addition, the team placed defensive back Ja'Sir Taylor on ...

Los Angeles announced receiver Simi Fehoko and cornerback Eli Apple have been activated to the 53-man roster off of injured reserve. Fehoko is back after dealing with an elbow injury and Apple had a ...

Los Angeles announced receiver Simi Fehoko and cornerback Eli Apple have been activated to the 53-man roster off of injured reserve. Fehoko is back after dealing with an elbow injury and Apple had ...

Apple, 29, is a former first-round pick of the Giants back in 2016. He was traded to the Saints two years later for a 2019 fourth-round pick and 2020 seventh-round pick. Apple was in the final ...

The Los Angeles Chargers today activated cornerback Eli Apple and wide receiver Simi Fehoko from Reserve/Injured; Designated for Return. In addition, the team placed defensive back Ja'Sir Taylor on ...

On Friday afternoon, the Chargers announced a handful of roster transactions ahead of their wild card matchup with the Texans. First up, the Bolts are activating both cornerback Eli Apple and wide ...

The 19-year-old phenom, who is set to finally take over as a starter in the 2025 season, said he has been bullied by his famous uncles, Peyton and Eli, and they have even given him wedgies.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

Eli Lilly (NYSE:LLY) is in advanced discussions to purchase cancer-focused biotech Scorpion Therapeutics for as much as $2.5 billion. A deal is likely to be reached in the coming days ahead of the ...

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue ...